News

STAT9h
New CBER director Vinay Prasad praises evidence, FDA reviewers in first speech to staff
WASHINGTON — In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his ...
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and ...
US FDA Names Agency Critic Vinay Prasad as Top Vaccine Official
(Reuters) -The U.S. Food and Drug Administration has named Vinay Prasad, an oncologist who has previously criticized FDA ...
STAT17h
Vinay Prasad is outraged, and now at the FDA. How will biotech deal?
Vinay Prasad, a skeptic of mainstream medicine, is now a top FDA official. Change is coming for some drugmakers, one way or ...
The FDA names a new vaccine chief with an unsettling record, joining a controversial team
Dr. Vinay Prasad, the FDA's new vaccine chief, has been accused of spreading misinformation about Covid vaccines.
The American Journal of Managed Care14h
Biotech Stocks Slide After FDA Selects Prasad to Lead CBER
The FDA's decision to appoint Vinay Prasad, MD, MPH, to head its Center for Biologics Evaluation and Research (CBER) raised ...
STAT22h
Women’s Health Initiative gets official word on funding
“Potential exposure to these substances is still quite small, thank goodness,” Jim Crotty, who served for over a decade in ...
Hosted on MSN21h
Sarepta price target lowered to $70 from $110 at Piper Sandler
The firm notes Tuesday has been “a doozy of a day” for Sarepta, with the announcement of Vinay Prasad as the new head of the FDA’s CBER and a miss on Q1 earnings, where Elevidys net revenue came in ...